Processa Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $3.4 million for the third quarter, slightly higher than the $3.4 million loss reported in the same period last year. For the nine months ending September 30, 2025, the net loss totaled $10.2 million, compared to $9.1 million for the same period in 2024. The increase in losses is attributed to rising general and administrative expenses, which surged by approximately $830,000 year-over-year, primarily due to higher salaries and investment management fees related to the company's cryptocurrency strategy.
In terms of operational metrics, Processa's total assets increased significantly to $7.6 million as of September 30, 2025, up from $3.2 million at the end of 2024. This growth was largely driven by a substantial increase in cash and cash equivalents, which rose to $6.3 million from $1.2 million at the end of the previous fiscal year. The company’s stockholders' equity also saw a notable increase, reaching $5.8 million, compared to $1.7 million at the end of 2024. This improvement reflects the successful completion of public offerings that generated net proceeds of approximately $10.6 million during the nine months ended September 30, 2025.
Strategically, Processa has been active in expanding its clinical pipeline and exploring innovative financial strategies. The company is currently developing its Next Generation Cancer therapies, with one candidate in a Phase 2 trial and another in preclinical development. Additionally, on August 7, 2025, Processa announced its intention to implement a corporate cryptocurrency treasury strategy, which includes acquiring and holding digital assets. As of September 30, 2025, the company held $350,000 in USD-backed stablecoins, with plans to increase this amount to $850,000 following subsequent investments.
The company’s operational focus remains on advancing its clinical trials, particularly for its NGC-Cap drug, which is being evaluated for advanced or metastatic breast cancer. Processa is also assessing the potential of its PCS499 drug for treating primary glomerular diseases, with plans to meet with the FDA in the fourth quarter of 2025 to discuss the design of a Phase 3 study. However, the company has acknowledged that it will continue to rely on equity and debt financing to support its operations, as it has not yet generated any product revenue and does not expect positive cash flow in the near future.
Looking ahead, Processa Pharmaceuticals faces challenges related to its liquidity and funding needs. The company has indicated that its current cash reserves may not be sufficient to sustain operations beyond the first quarter of 2026 without additional financing. As such, it plans to pursue various funding avenues, including public or private equity offerings and strategic partnerships, to ensure the continuation of its clinical development programs. The company’s ability to execute its long-term plans will depend on securing adequate financing under favorable terms.
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Cancer therapies by modifying existing, well-understood cancer drugs to enhance efficacy and reduce toxicity. Its pipeline includes small molecules in Phase 2 trials targeting solid tumors, with a focus on improving safety profiles. The company leverages proprietary regulatory science to streamline development and aims for rapid adoption of more effective, less toxic cancer treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.